Abstract：Objective: To observe the effects of tenofovir disoproxil fumarate combined with Fuzheng Huayu on liver fibrosis degree and immune status of patients with hepatitis B cirrhosis.Methods: A total of 150 patients with hepatitis B cirrhosis who were treated in our hospital from January 2018 to June 2019 were selected as subjects, and they were divided into observation group and control group according to the simple random grouping, with 75 cases in each group. Control group was treated with tenofovir disoproxil fumarate, and observation group was combined with Fuzheng Huayu on the basis of control group, and the two groups took 24 weeks as a course of treatment. The liver function [alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), albumin (ALB)], liver fibrosis indicators [hyaluronic acid (HA), laminin (LN), type III procollagen (PC III), type IV collagen (IV-C)], virological indicators [negative conversion rate of hepatitis B virus gene (HBV DNA negative conversion rate), negative conversion rate of hepatitis B virus e antigen (HbeAg negative conversion rate)], imaging indicators (portal vein diameter, portal vein blood flow velocity, spleen thickness, spleen length, portal blood flow) and immune function (CD3+, CD4+, CD8+, CD4+/CD8+) were compared between the two groups before treatment and after 24 weeks of treatment, and the occurrence of adverse reactions during treatment were recorded in the two groups. Results: Before treatment, there were no statistically significant differences in the ALT, AST, TBIL, ALB, HA, LN, PC III, IV-C, portal vein diameter, portal vein blood flow velocity, spleen thickness, spleen length, portal blood flow, CD3+, CD4+, CD8+ and CD4+/CD8+ between the two groups (all P>0.05). After 24 weeks of treatment, the ALT, AST, TBIL, HA, LN, PC III, IV-C, portal blood flow and CD8+ in the two groups were significantly lower than those before treatment (all P<0.05) while the ALB, portal vein blood flow velocity, CD3+, CD4+ and CD4+/CD8+ were significantly higher than those before treatment (all P<0.05). There were no statistically significant differences in the differences of ALT, AST, TBIL and ALB before and after treatment between the two groups (all P>0.05), and the differences of HA, LN, PC III, IV-C, portal vein blood flow velocity, portal blood flow, CD3+, CD4+, CD4+/CD8+ and CD8+ before and after treatment in observation group were significantly higher than those in control group (P<0.05). After 24 weeks of treatment, there were no statistically significant differences in the HBV DNA negative conversion rate and HbeAg negative conversion rate between the two groups (P>0.05). The total incidence rate of adverse reactions was 6.67% in observation group and was 4.00% in.control group (χ2=0.528, P=0.467). Conclusion: Tenofovir disoproxil fumarate combined with Fuzheng Huayu can indeed effectively improve the liver function, alleviate the liver fibrosis degree, accelerate portal vein blood flow and help improve the immune function, and it is safe and reliable, and is beneficial to the disease outcomes.
胡会芬, 刘雯, 谭林. 富马酸替诺福韦联合扶正化瘀治疗对乙肝肝硬化患者肝纤维化程度及免疫状态的影响[J]. 河北医学, 2021, 27(4): 686-692.
HU Huifen, LIU Wen, TAN Lin. Effects of Tenofovir Disoproxil Fumarate Combined with Fuzheng Huayu on Liver Fibrosis Degree and Immune Status of Patients with Hepatitis B Cirrhosis. HeBei Med, 2021, 27(4): 686-692.
[1] A J L,B M Q,A A G,et al.Quantification of degree of liver fibrosis using fibrosis area fraction based on statistical chi-square analysis of heterogeneity of liver tissue texture on routine ultrasound images[J].Academic Radiology,2019,26(8):1001~1007. [2] Verloh N,Utpatel K,Haimerl M,et al.DWI - histology: a possible means of determining degree of liver fibrosis[J].Oncotarget,2018,9(28):20112~20118. [3] Liu K,Choi J,Le A,et al.FRI-193-Long-term renal and bone safety of tenofovir disoproxil fumarate in chronic hepatitis B patients with cirrhosis[J].Journal of Hepatology,2019,70(1):475~476. [4] 王姬,盛吉芳,周建芳,等.扶正化瘀胶囊联合恩替卡韦治疗乙型肝炎肝硬化的疗效观察[J].中国中西医结合杂志,2018,38(12):1430~1434. [5] 陈日霞.扶正化瘀胶囊联合恩替卡韦治疗慢性乙型肝炎肝纤维化的疗效和安全性[J].肝脏,2019,24(9):118~119. [6] 中华医学会肝病学分会;中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版)[J].实用肝脏病杂志,2016,19(3):389~400. [7] Jeong J Y,Cho Y S,Sohn J H.Role of two-dimensional shear wave elastography in chronic liver diseases: a narrative review[J].World Journal of Gastroenterology,2018,24(34):41~52. [8] Nishie A,Akahori S,Asayama Y,et al.Prediction of liver fibrosis using CT under respiratory control: new attempt using deformation vectors obtained by non-rigid registration technique[J].Anticancer research,2019,39(3):1417~1424. [9] Yokoo T,Kanefuji T,Suda T,et al.Rational arrangement of measuring shear wave speed in the liver[J].World Journal of Gastroenterology,2019,25(20):2503~2513. [10] 沈伟,陈彬,范久波,等.恩替卡韦和替诺福韦酯治疗乙型肝炎肝硬化的实验室及超声指标比较[J].现代仪器与医疗,2019,25(1):49~53. [11] 陈仕,周艳,耿颖.扶正化瘀胶囊联合恩替卡韦治疗乙型肝炎后肝硬化的疗效及对肝纤维化指标及免疫功能的影响[J].医学临床研究,2018,35(7):1385~1387. [12] 申恩华,王茉莉,王立红,等.恩替卡韦和富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎及乙型肝炎肝硬化抗病毒效果[J].中国医药导报,2018,15(28):70~73.
2021, Vol. 27 
冀公网安备13080202000677号